Compare DexCom, Inc. (DXCM) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Weibo Corp — how do they compare? DexCom, Inc. trades at $84 (market cap $31.86B), while Weibo Corp trades at $6.55 (market cap $1.56B). The key difference: DexCom, Inc. is far larger — about 20.4× Weibo Corp's market cap, and Weibo Corp pays a 9.47% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Weibo Corp for 102 Days on average.
| DXCM | WB | |
|---|---|---|
Market Cap | $31.86B | $1.56B |
Volume | 3,607,070 | 812,503 |
Sector | Health | Media |
52-Week High | $92.34 | $12.37 |
52-Week Low | $54.84 | $6.33 |
Typical Hold Time | 62 Days | 102 Days |
Enterprise Value | $31.32B | $786.69M |
Dividend Yield | — | 9.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
Weibo (WB) trades at $6.55, up 1.08% on the day, with a bearish technical signal. The stock is fundamentally attractive with a low P/E of 5.32 and P/B of 0.4, while profitability remains solid with a net income margin of 17.78%. Recent Q2 2026 earnings beat expectations, though revenue growth is modest. Cash flow trends show volatility, with a significant net outflow in 2024.
The outlook is mixed; deep-value metrics and strong cash generation offer upside, but declining user metrics and advertising headwinds pose risks. Analyst consensus is divided, leaning slightly toward Hold. The stock presents a value opportunity for patient investors, contingent on stabilizing user engagement and advertising demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
